RWE 201 – EU – EU’s Action Plan for Real-World Data (RWD) & RWE
The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) into the fabric of its healthcare system. The strategy, underscored by a comprehensive multi-year plan, focuses on harnessing the power of real-world data (RWD) through collaboration, standardization, and innovation. The infrastructure for this integration outlines seven pivotal components: Terminology, Findability, Access, Quality, Advanced Analytics, Use, and Use Cases.
RWE 2020 – The Foundation: The EU emphasizes on the importance of RWD Collection and RWE Generation. Key pillars of this foundational year include:
– Enhancing collaboration nationally and across borders.
– Creating a robust framework with effective methodologies.
– Recognizing the role of RWE in supplementing clinical trials.
– Aiming to support decisions by regulators, HTA, and payers.
– Advocating support for healthcare providers.
2021:
– Focuses on access to RWD and the establishment of the EU4Health Program.
– Introduction of new legislations: Artificial Intelligence Regulation, Health Technology Assessment Regulation, and laws on RWE Value and RWD Access.
– Notably, a step towards centralized data governance with the European Health Data Space Regulation.
2022:
– Expands on the RWE Use Cases with guidelines and draft laws.
– Emphasis on medicinal product regulations.
– The Data Governance Act aims to support data access and streamline data utilization.
2023:
– Proliferation of RWE use cases continues.
– Medicinal Products Regulation is in the limelight alongside explorations into single-arm trials by EMA.
– The year marks a notable focus on AI with the EMA’s guidance on Artificial Intelligence.2024:
– The direction is set towards advanced RWD analytics and a broader scope of RWE Use Cases.
– Introduces a Catalogue of NIS using RWD Sources and a focus on RWD findability with source catalogues = The replacement for the EU PAS Register
This roadmap not only outlines the EU’s commitment to innovative healthcare solutions but also sets a precedent for global health systems to leverage real-world data and evidence for enhanced patient care.
Share this story...
Real World Evidence (RWE) 201 – Beyond Clinical Trials: Health Canada’s Commitment to Real World Evidence
RWE 201 - Beyond Clinical Trials: Health Canada's Commitment to Real World Evidence Health Canada is dedicated to enhancing drug accessibility, affordability, and correct usage within the country. To [...]
Real World Evidence (RWE) 201 – A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA
RWE 201 - A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA Non-interventional studies are different from randomized controlled trials (RCTs). Instead of actively intervening in a [...]
Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
RWE 201 - FDA's Advancing RWE Program Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. [...]
Real World Evidence (RWE) 201 – FDA’s RWE Considerations Draft Guidance
RWE 201 - FDA's RWE Considerations Draft Guidance The 21st Century Cures Act, signed into law in 2016, mandated the FDA to establish a framework for the evaluation of [...]
Real World Evidence 201 – FDAs RWE Framework
RWE 201 - FDAs RWE Framework Real World Evidence (RWE) 201 – FDAs RWE Framework RWE 201: https://rwr-regs.com/rwe-201/ The FDA's Real-World Evidence (RWE) Program framework, established under the [...]
Real World Evidence 201 – The 21st Century Cures Act
RWE 201 - The 21st Century Cures Act The 21st Century Cures Act (CURES 1.0), signed into law in the U.S. in December 2016, aimed to accelerate [...]
